ライフサイエンスコーパス: melatonin receptor

1 tigate the nature of the binding site of the melatonin receptor.

2 consistent with its assignment as encoding a melatonin receptor.

3 by melatonin is mediated via a G(i)-coupled melatonin receptor.

4 tional assays on recombinant mt(1) and MT(2) melatonin receptors.

5 to differences in the density or affinity of melatonin receptors.

6 have been identified including glutamate and melatonin receptors.

7 se binding sites represent G protein-coupled melatonin receptors.

8 nuclear receptors, such as Rev-ErbA and the melatonin receptors.

9 pendent of an effect on the classic membrane melatonin receptors.

10 LNs for a community containing serotonin and melatonin receptors.

11 the opsins share a common ancestor with the melatonin receptors.

12 activity occurs through activation of MT(2) melatonin receptors.

13 through activation of G protein-coupled MT2 melatonin receptors.

14 control cells suggesting a partial role for melatonin receptors.

15 ly increases photoreceptor responses through melatonin receptors.

16 and depression/anxiety-related behavior in a melatonin receptor 1 (MT1)-dependent manner.

17 iability, migration, and binding affinity to melatonin receptor 1 (MT1R) and estrogen receptor 1 (ESR

18 ctivity at adenosine receptor 1 (ADORA1) and melatonin receptor 1 (MTNR1A).

19 We report that melatonin receptor 1 inhibits mobilization of L1 in cult

20 The human MT(1) and MT(2) melatonin receptors(1,2) are G-protein-coupled receptors

21 ifferentially methylated CpG site within the melatonin receptor 1A (MTNR1A) gene mediates the effect

22 IOP cohorts identified multiple variants in melatonin receptor 1A (MTNR1A) with a potential pathogen

23 is in cholestatic models by interaction with melatonin receptors 1A (MT1) and 1B (MT2).

24 Neither melatonin receptor-1a, nor -1b, were found to be express

25 tween glucose change and rs10830963:G in the melatonin receptor 1B (B [SE] -0.23 [0.03], P = 2.15 x 1

26 Interactions between polymorphisms of the melatonin receptor 1B (MTNR1B) gene and lifestyle interv

27 Variants in the gene encoding melatonin receptor 1B (MTNR1B) were consistently associa

28 The T2D risk variant in the melatonin receptor 1B gene (MTNR1B) predicted risk of PO

29 ell as the duration of single calls, and (3) melatonin receptor 1b is highly expressed in evolutionar

30 anelle transport and signaling downstream of melatonin receptor [3, 4].

31 duced phase shifts of locomotor behavior and melatonin receptors activate G-protein-coupled inwardly

32 at this protective capacity may also rely on melatonin receptor activation.

33 ity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative

34 ramelteon, a potent and clinically relevant melatonin receptor agonist, significantly affect the neu

35 Finally, application of ramelteon, a potent melatonin receptor agonist, significantly decreased firi

36 nce) of once-daily tasimelteon, a novel dual-melatonin receptor agonist.

37 which we tested the efficacy of ramelteon, a melatonin-receptor agonist used to treat insomnia, versu

38 as designed to investigate whether selective melatonin receptor-agonist ramelteon may influence survi

39 to 1.07]; IC, - 0.30 [IC(025), - 0.77]) and melatonin receptor agonists (ROR, 1.20 [0.80 to 1.81]; I

40 s, antihypertensive drugs, antiviral agents, melatonin receptor agonists, anticholesterol and antican

41 ays, such as orexin receptor antagonists and melatonin receptor agonists, offer promising strategies

42 ts, orexin receptor agonists, melatonin, and melatonin receptor agonists.

43 an rhythms by activation of a membrane-bound melatonin receptor and strongly suggests that this effec

44 The indolamine acts through melatonin receptors and binds to different proteins such

45 KII is activated by melatonin and downstream melatonin receptors and may be the common effector in th

46 ction, at least in birds, since they express melatonin receptors and melatonin affects their metaboli

47 ulates dopamine release by the activation of melatonin receptors and that endogenous melatonin modula

48 olecular foundation of ligand recognition by melatonin receptors, and will facilitate the design of f

49 larization-evoked calcium increases, and the melatonin receptor antagonist 4-P-PDOT blocked this effe

50 n of human blood with exogenous melatonin or melatonin receptor antagonist during the in situ perfusi

51 d this effect was blocked by the competitive melatonin receptor antagonist luzindole (100-1000 nM).

52 investigated by intravitreally injecting the melatonin receptor antagonist luzindole into rats.

53 reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin,

54 of both luzindole, a reference MT2-selective melatonin receptor antagonist, and melatonin.

55 Luzindole (1 microM), a competitive melatonin receptor antagonist, antagonized the effect of

56 1/1.0/10 mg/kg; mice: 1.0 mg/kg), ramelteon, melatonin receptor-antagonist luzindole, ramelteon + luz

57 Neither the selective MT2 melatonin receptor antagonists 4P-ADOT and 4P-PDOT (90 m

58 The addition of melatonin receptor antagonists abolishes the MT1 effect

59 Treatment with melatonin receptor antagonists at night dramatically imp

60 tonin in development is unknown, even though melatonin receptors appear to be more highly expressed i

61 Loss-of-function mutations in the melatonin receptor are associated with insulin resistanc

62 Moreover, receptors for serotonin and melatonin receptors are expressed in keratinocytes, mela

63 Although G protein-coupled MT1 and MT2 melatonin receptors are expressed in neurons of the mamm

64 Melatonin receptors are expressed in retinal photorecept

65 Melatonin receptors are expressed in several cell types

66 This study indicates that Mel1a and Mel1b melatonin receptors are expressed specifically in the Xe

67 Drugs acting on melatonin receptors are indicated for circadian rhythm-

68 in the pars distalis (PD) of the pituitary, melatonin receptors are localized in the pars tuberalis

69 lmodulin kinase II stimulation of downstream melatonin receptors as well as the participation of this

70 Melatonin receptors bind and become activated by melaton

71 e, and luzindole, a competitive inhibitor of melatonin receptor binding, were examined for their abil

72 illustrates the opportunities for modulating melatonin receptor biology through MT(1)-selective ligan

73 These modulatory effects were diminished by melatonin receptor blockade and pertussis toxin (PTX).

74 -min nicotine exposure; and (4). the role of melatonin receptors (by pertussis toxin inhibition) on n

75 In the present work, the mouse Mel(1b) melatonin receptor cDNA was isolated and characterized,

76 Eyes pretreated with the melatonin receptor competitive antagonist luzindole befo

77 ne rhythms in mammals; the data suggest that melatonin-receptor-containing cells in the pituitary gla

78 A pharmacological block of melatonin receptors delays neurogenesis and reduces neur

79 nsiderable amino acid sequence identity with melatonin receptors, does not bind melatonin and is curr

80 r plasma melatonin concentration and a lower melatonin receptor expression in the anterior cingular c

81 ification of 2-[125I]iodomelatonin and Mel1a melatonin receptor expression in the fetal leptomeninges

82 cent efforts to clone further members of the melatonin receptor family have led to the identification

83 Blockade of melatonin receptor function by pre-exposure to pertussis

84 ls, while among humans, polymorphisms in the melatonin receptor gene are associated with insulin resi

85 Melatonin receptors have been identified in several reti

86 Furthermore, hMT2-GFP melatonin receptors heterologously expressed in immortal

87 or 7-70 pg/mL) decreased the number of hMT2 melatonin receptors heterologously expressed in mammalia

88 onstrates the involvement of the MT2 (Mel1b) melatonin receptor in mediating phase advances of circad

89 The role of retinal melatonin receptors in modulating light-damage susceptib

90 ests that melatonin, acting through specific melatonin receptors in ocular tissues, plays a role in o

91 expression and signaling of MT(1) and MT(2) melatonin receptors in SCN2.2 cells.

92 ion of melatonin desensitizes endogenous MT2 melatonin receptors in the mammalian SCN thereby providi

93 These results suggest multiple roles for melatonin receptors in the regulation of astroglial func

94 nin at night from the pineal gland activates melatonin receptors in the suprachiasmatic nucleus of th

95 The human ML1A melatonin receptor is expressed in the suprachiasmatic n

96 s demonstrated that mRNA for MT(1) and MT(2) melatonin receptors is expressed mostly in cells with ne

97 t variation in the number and/or location of melatonin receptors is the basis for individual differen

98 cadian signaling, conveyed through a mutated melatonin receptor, is incompatible with rod photorecept

99 on of melatonin, combined with expression of melatonin receptors, is involved in the regulation of th

100 ctivity, and agonist behavior of these novel melatonin receptor ligands based on superposition models

101 erposition models guided the design of novel melatonin receptor ligands characterized by a 2-acylamin

102 To assess melatonin receptor localization in the OPL, double-label

103 super high affinity state of the human ML1A melatonin receptor may be the mechanism by which low con

104 Since the Mel1a melatonin receptor may transduce the major neurobiologic

105 Melatonin receptors mediate improvements of survival aft

106 pes will allow molecular dissection of other melatonin receptor-mediated responses.

107 r growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels,

108 However, the organization of the melatonin receptors mediating this action in the outer p

109 detected expression of the G protein-coupled melatonin receptor Mel1a, but not Mel1b.

110 the first time the expression of mt1 and MT2 melatonin receptor mRNA within the suprachiasmatic nucle

111 Melatonin receptors MT(1) and MT(2) are involved in sync

112 polymicrobial sepsis in rats, wild-type and melatonin receptor MT1/MT2 double knockout mice.

113 ave been identified as novel agonists of the melatonin receptors MT1 and MT2.

114 humans is associated with loss of the type 1 melatonin receptor (MT1).

115 They can act on G-protein-coupled melatonin receptors (MT1 and MT2) as well as nuclear ary

116 ive effects of melatonin, while the membrane melatonin receptors (MT1 or MT2) did not change the acti

117 y1) or negatively (exemplified by the type 1 melatonin receptor, mt1).

118 New compounds were fully characterized at melatonin receptors (MT1R and MT2R), and results were ra

119 that a small deletion mutation of the Mel1a melatonin receptor (mtnr1a) gene causes a loss of rod ph

120 The decrease in MT2 melatonin receptor number induced by melatonin (300 pM f

121 the current status in the emerging field of melatonin receptor oligomerization are critically discus

122 wn about the influence of native MT1 and MT2 melatonin receptors on neuronal melatonin signaling.

123 Targeted disruption of the Mel(1a) melatonin receptor prevents some, but not all, responses

124 MT(1) and MT(2) melatonin receptor proteins are expressed in both rat SC

125 ression of the Mel(1a), Mel(1b), and Mel(1c) melatonin receptor proteins in ocular tissues was examin

126 from both chick and mouse brains, expressed melatonin receptor proteins.

127 onclude that SCN2.2 cells express functional melatonin receptors, providing an in vitro model to unve

128 Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved f

129 reviously found a differential impairment of melatonin receptor signaling in AIS osteoblasts allowing

130 ould accordingly envisage that disruption of melatonin receptor signaling is detrimental to photorece

131 way and agonist regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster o

132 RNA distribution and transcript abundance of melatonin receptor subtype 1B (mel1b), shown to be impor

133 We conclude that the MT2 melatonin receptor subtype is a novel therapeutic target

134 study was to determine the expression of the melatonin receptor subtype proteins in chick ocular tiss

135 s contribute to a molecular understanding of melatonin receptor subtype selectivity and ligand access

136 that this effect is mediated through the MT2 melatonin receptor subtype within the circadian timing s

137 The other melatonin receptor subtype, the Mel1b receptor, is expre

138 Results of this study show that all three melatonin receptor subtypes are expressed in retinal and

139 Two high-affinity, G protein-coupled melatonin receptor subtypes have been identified in mamm

140 Mice with targeted disruption of melatonin receptor subtypes will allow molecular dissect

141 rovide insights into the selectivity between melatonin receptor subtypes.

142 The Xenopus melatonin receptor thus cannot accommodate an N-n-alkyl

143 e that the pattern of expression of neuronal melatonin receptor types in different brain areas and ce

144 ocal immunohistochemistry for Mel1a or Mel1b melatonin receptors was performed in combination with ma

145 xemplification in one particular target, the melatonin receptor, where following this procedure led t

146 ighttime surges in melatonin levels activate melatonin receptors, which synchronize cellular activiti

147 o as H9, is clearly related to high-affinity melatonin receptors yet unable to bind this hormone.